AKB-9778: Phase IIa data

Top-line data from the double-blind, U.S. Phase IIa TIME-2 trial in 144 patients showed that twice-daily 15 mg subcutaneous AKB-9778

Read the full 208 word article

How to gain access

Continue reading with a
two-week free trial.